Analyst Rating Update on Charles River Laboratories International (CRL)

Charles River Laboratories International (CRL) : 14 analysts are covering Charles River Laboratories International (CRL) and their average rating on the stock is 2, which is read as a Buy. 8 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 5 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.

Charles River Laboratories International (CRL) : 9 investment research analysts covering Charles River Laboratories International (CRL) have an average price target of $86.78 for the near short term. The highest target price given by the Brokerage Firm to the stock is $97 and the lowest target is $65 for the short term. Analysts expect the variance to be within $10.01 of the average price.

For the current week, the company shares have a recommendation consensus of Buy.


Charles River Laboratories International (NYSE:CRL): The stock opened at $89.04 on Wednesday but the bulls could not build on the opening and the stock topped out at $89.18 for the day. The stock traded down to $85.76 during the day, due to lack of any buying support eventually closed down at $85.96 with a loss of -1.24% for the day. The stock had closed at $87.04 on the previous day. The total traded volume was 940,074 shares.

Charles River Laboratories International, Inc. is a full service, early stage contract research company. The Company offers research models for the research and development of new drugs, devices and therapies. It develops a portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP that support the clients from target identification through preclinical development. The Company operates through three segments: Research Models and Services (RMS), which supplies research models to the drug development industry; Discovery and Safety Assessment (DSA), which provides services that enables the clients to outsource their drug discovery research, critical, regulatory-required safety assessment testing and related drug discovery and development activities, and Manufacturing Support (Manufacturing), which is involved in the production and release of products manufactured by the clients.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *